FCPA Compliance Roadmap for Drug and Device Companies.gif

FCPA Compliance Roadmap for Drug and Device Companies - Webinar CD/Transcript

Quantity Discounts
1 - 2
3 - 4
5 - 6
7 - 9
10 - 99

FCPA Compliance Roadmap for Drug and Device Companies: Lies, Misconceptions and Traps that Cost Firms Millions

Drug and device firms that violate the Foreign Corrupt Practices Act (FCPA) risk untold fines and hassles — and even criminal charges.

If you do business internationally — read this NOW.

Ever commit a crime? Probably not. But recently many top pharma and device companies have, and paid dearly.

Each year the list of FCPA violators gets longer and the fines go up.

In just the last two years, five major drug and device companies have been prosecuted and paid nearly $150 million in fines, disgorgement of profits, penalties and interest.

In 90 riveting minutes, top international Washington lawyers Michael Burke and Ed Cadigan of Arnall Golden Gregory LLP reveal lies and misconceptions that can ensnare drug and device firms, leading to noncompliance with FCPA. You’ll discover —

  • The 10 misconceptions that may expose your firm to FCPA risk …
  • Recent changes to FCPA enforcement that impact life sciences companies …
  • How to identify FCPA red flags …
  • Supply-chain vulnerabilities — when a supplier gets you in trouble …
  • Managing an effective FCPA compliance program — steps to take now
  • Mitigating FCPA risk in contracts such as distribution agreements …
  • Potential interplay between the FCPA and the UK Bribery Act …
  • And much more!

The matter couldn’t be more timely. The Justice Dept. says it will step up FCPA enforcement against life sciences companies of all kinds. And Justice and the Securities & Exchange Commission have formed special “FCPA Units” dedicated to ferreting out FCPA violations across the corporate spectrum.

Considering the huge liability potential of an FCPA violation, it’d be well worth the expense and hassle — not to mention days away from work and family — to fly to Washington for this learning experience. Good thing you don’t have to. You participate from the convenience of your office, conference room or auditorium. The conference comes to you.

With millions of dollars and years of international legal woes potentially on the line, there’s no excuse for not protecting yourself and your organization.

  • General/corporate counsel
  • Auditors
  • Compliance officers
  • Regulatory professionals
  • Executive management 
  • Manufacturing directors and supervisors
  • Sales/marketing personnel
  • Strategic planning and business development staff
  • Training personnel
  • New hires

Your Expert Presenters

Michael Burke is a Corporate Practice partner with Arnall Golden Gregory LLP, specializing in FCPA investigations and compliance program development with a focus on U.S. export controls, economic sanctions and anti-boycott regulations. He advises clients on mergers and acquisitions, joint ventures and strategic alliances, private equity, distribution and reseller networks, and technology licensing.

Ed Cadagin is an associate in the Litigation and Employment Practice Groups of Arnall Golden Gregory. At Georgetown Law, Mr. Cadagin was chosen to be a Legal Research & Writing Law Fellow and an extern for the Department of Justice, Criminal Division – FCPA Unit. Prior to Arnall Golden Gregory, he practiced employment law with an international Washington DC law firm.